USD
+$0.00
(+0.00%
)At Close (As of Sep 3, 2025)
-
Market Cap
-
P/E Ratio
-
EPS
$38.00
52 Week High
$4.50
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$7.6M |
Selling General And Administrative | $6.4M |
Research And Development | $1.2M |
Operating Expenses | $7.6M |
Investment Income Net | - |
Net Interest Income | -$786K |
Interest Income | - |
Interest Expense | $786K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | -$8M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$8M |
Comprehensive Income Net Of Tax | - |
Ebit | - |
Ebitda | -$7.2M |
Net Income | -$8M |
Field | Value (USD) |
---|---|
Total Assets | $1.4M |
Total Current Assets | $1.4M |
Cash And Cash Equivalents At Carrying Value | $513K |
Cash And Short Term Investments | $513K |
Inventory | - |
Current Net Receivables | $40K |
Total Non Current Assets | $0 |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $815K |
Other Non Current Assets | - |
Total Liabilities | $4.1M |
Total Current Liabilities | $4.1M |
Current Accounts Payable | $1.9M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.2M |
Total Non Current Liabilities | $0 |
Capital Lease Obligations | - |
Long Term Debt | - |
Current Long Term Debt | $2.2M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $2.2M |
Other Current Liabilities | - |
Other Non Current Liabilities | - |
Total Shareholder Equity | -$2.7M |
Treasury Stock | - |
Retained Earnings | -$21M |
Common Stock | $613 |
Common Stock Shares Outstanding | $6.1M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$5.8M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | - |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | - |
Cashflow From Financing | $6.2M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$167K |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$8M |
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$7.6M |
Selling General And Administrative | $6.4M |
Research And Development | $1.2M |
Operating Expenses | $7.6M |
Investment Income Net | - |
Net Interest Income | -$786K |
Interest Income | - |
Interest Expense | $786K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | -$8M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$8M |
Comprehensive Income Net Of Tax | - |
Ebit | - |
Ebitda | -$7.2M |
Net Income | -$8M |
Sector: LIFE SCIENCES
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company is headquartered in Durham, North Carolina.